Home / Themes / Genomics '25: Genomics Tools, Reagents & Workflows
Last updated
Theme no thesis · 2/5 sections · Tickers 6 with notes · 6 pending
Bull / Bear Details has the investment thesis and bull/bear points. Overview is monitoring guidance (hiring, forums, second-order trends, search keywords, Google Trends, datasets).
Discussions on new sequencing technologies, data analysis challenges, and general industry sentiment.
Practical insights and user experiences with lab automation equipment, reagents, and workflow issues.
Trends in genomic data processing, software tools, AI applications in data interpretation, and computational challenges.
Discussions on new automation systems, industry best practices, technological advancements, and workforce needs.
Insights into IT infrastructure for genomics, data management, cloud solutions, and integration of AI in biotech.
Not in registry
Metric/field Total Venture Capital Funding for Biotech/Pharma Sector (USD billions)
Cadence quarterly
Why it matters Direct funding for emerging biotech companies, which are key customers for genomics tools and automation. Increased funding leads to more R&D, more labs, and more equipment purchases.
Signal to watch Sustained increase in funding = bullish
Confidence: high
Not in registry
Metric/field Total NIH Obligations (USD billions)
Cadence annually
Why it matters Major source of funding for academic and government research, a significant customer segment for many theme constituents.
Signal to watch Increase in budget/grant awards = bullish
Confidence: high
Not in registry
Metric/field Purchasing Managers' Index (PMI) - Manufacturing (Diffusion Index)
Cadence monthly
Why it matters Broader economic health indicator. A strong manufacturing sector can indicate higher corporate spending and confidence, including in R&D and capital expenditures for labs. A reading above 50 indicates expansion.
Signal to watch PMI > 50 and rising = bullish
Confidence: high
Not in registry
Metric/field Federal Funds Target Rate Upper Bound (Percentage)
Cadence event_driven
Why it matters Cost of capital impacts investment decisions for both companies (capex) and startups (funding availability). Lower rates generally encourage investment.
Signal to watch Stable or decreasing rates = bullish
Confidence: high
Not in registryaccess=api
Metric/field Real Gross Domestic Product (GDP) - Percent Change from Preceding Quarter, Annualized
Cadence quarterly
Why it matters Overall economic growth drives demand across industries, including healthcare and life sciences, influencing R&D budgets and diagnostic testing volumes.
Signal to watch Accelerating GDP growth = bullish
Confidence: high
Matched (medium)engine_advertising_brand_tracking · access=file · map_only
Metric/field Number of job postings for 'Computational Biologist' or 'Automation Engineer' by theme constituents (e.g., Agilent, Qiagen, Twist Bioscience)
Cadence irregular
Why it matters Direct indicator of hiring intent and investment in key areas of the genomics and automation workflow by the companies themselves.
Signal to watch Sustained increase in relevant job postings = bullish
Confidence: medium
Not in registry
Metric/field Search interest for 'AI drug discovery' (worldwide) or 'spatial biology' (worldwide)
Cadence weekly
Why it matters Reflects public and industry interest in major drivers for synthetic biology and genomics tools. Increased interest can precede increased investment.
Signal to watch Rising search interest = bullish
Confidence: medium
Not in registry
Metric/field Number of new studies registered with keywords 'genomics' OR 'spatial biology' in intervention/condition fields
Cadence weekly
Why it matters Indicates the volume of new clinical research utilizing genomics and spatial biology technologies, suggesting future demand for tools and services.
Signal to watch Increasing number of relevant clinical trials = bullish
Confidence: high
Not in registry
Metric/field Number of new publications with keywords 'genomics automation' OR 'spatial transcriptomics' (last 30 days)
Cadence monthly
Why it matters Reflects the pace of scientific advancement and adoption of these technologies in research, indicating a growing user base and potential for commercialization.
Signal to watch Rising publication volume = bullish
Confidence: medium
Not in registryaccess=api
Metric/field Total federal grant awards for 'life sciences research' (USD millions) by recipient type (e.g., universities, research institutions)
Cadence quarterly
Why it matters Direct measure of government investment in life sciences, which fuels academic and institutional demand for genomics tools.
Signal to watch Increasing grant awards = bullish
Confidence: high
Matchedtegus_expert_interview_transcripts · access=file · map_only
Metric/field Frequency and sentiment of mentions of 'genomics workflow automation' or 'spatial biology adoption' in expert calls related to theme constituents
Cadence irregular
Why it matters Provides qualitative insights into market sentiment, competitive dynamics, and real-world adoption trends from industry insiders.
Signal to watch Increasing positive mentions or discussions of adoption = bullish
Confidence: high
Not in registryaccess=file
Metric/field Growth rate of 'Research Scientist - Genomics' or 'Lab Automation Specialist' job postings by theme constituents
Cadence weekly
Why it matters More granular and aggregated view of hiring trends than manual checks, offering a leading indicator of R&D investment and expansion within the theme.
Signal to watch High and accelerating growth rate = bullish
Confidence: high
Matchedgartner_it_spending_market_forecasts · access=file · map_only
Metric/field Global spending on 'Next-Generation Sequencing (NGS) instruments' (USD millions) or 'Automated Liquid Handling Systems' (USD millions)
Cadence irregular
Why it matters Direct measure of capital expenditure on core genomics tools and automation, indicating market growth and demand for instruments.
Signal to watch Increasing spending = bullish
Confidence: medium
Matched (medium)s_p_global_trade_supply_chain_data · access=file · map_only
Metric/field Number of new 'bioprocessing facility expansions' or 'single-use technology adoption' projects by biopharma companies
Cadence irregular
Why it matters Bioprocessing is a key area for DHR and TMO. Tracking new projects indicates investment in manufacturing capacity, which drives demand for related tools and automation.
Signal to watch Rising number of new projects = bullish
Confidence: high
Not in registry
Metric/field Quarterly venture capital funding for 'genomics startups' (USD billions)
Cadence quarterly
Why it matters Specific to the genomics sector, this provides a more targeted view of early-stage investment that directly impacts the customer base for genomics tools and automation.
Signal to watch Increasing quarterly funding = bullish
Confidence: high
| Catalyst ID | Estimated Timing | Estimated Date Start | Estimated Date End | Catalyst | Why It Matters | Ticker Or Theme Specific | Transcript Date | Source Type | Catalyst Source |
|---|---|---|---|---|---|---|---|---|---|
| A_8bb5aafd | at the end of our fiscal year | 2026-10-01 | 2026-10-31 | Initial orders from large pharma customers for reshoring operations to the U.S. | This represents a strong tailwind for Agilent's downstream manufacturing QA/QC workflows, aligning with broader industry trends and potentially driving future revenue starting in FY27. | Ticker | 2026-05-27 | earnings_transcript | A (ticker) |
| BRKR_9d0e9826 | coming into the fourth quarter | 2026-10-01 | 2026-12-31 | Delivery and installation of an ultra-high field NMR system in Q4 2026. | The delivery of this high-value system is expected to contribute to a favorable mix and significantly higher volume in Q4, boosting revenue and profitability for the quarter. | Ticker | 2026-08-04 | earnings_transcript | BRKR (ticker) |
| QGEN_61c17649 | by the end of the year | 2026-10-01 | 2026-12-31 | FDA approval for QIAstat BCID (Bloodstream Infection Detection) panels in the U.S. | This approval will enable the expansion of the QIAstat-Dx menu into the critical U.S. bloodstream infection testing market, driving future revenue growth and strengthening the platform's competitive position. | Ticker | 2026-08-05 | earnings_transcript | QGEN (ticker) |
| TWST_1d572939 | November | 2026-11-01 | 2026-11-30 | Release full year fiscal 2027 guidance. | This will provide investors with a clearer financial outlook for the upcoming fiscal year, influencing sentiment and valuation. | Ticker | 2026-08-03 | earnings_transcript | TWST (ticker) |
